This listing of claims will replace all prior versions of claims in the application.

Listing of claims:

Claims 1-6. (cancelled)

7. (original) A compound of the following Formula:

$$(\mathbb{R}^2)_{\mathrm{m}}$$
 \mathbb{W} \mathbb{R}^{N} \mathbb{N} \mathbb{N}

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

optionally substituted alkylsulfonyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

W is optionally substituted methylene, -S-, -O-, optionally substituted -N-, -S(O)- or -S(O₂)-;

m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; and pharmaceutically acceptable salts thereof.

- 8. (original) A compound of claim 7 wherein W is optionally substituted methylene.
 - 9. (original) A compound of the following Formula:

$$(\mathbb{R}^2)_{\mathrm{m}}$$
 $(\mathbb{R}^2)_{\mathrm{m}}$
 $(\mathbb{R}^3)_{\mathrm{n}}$

wherein R is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl; optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or

heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

each R² and each R³ are independently hydrogen, halogen, hydroxyl, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

Y is optionally substituted methylene, -O-, -S-, -S(O)-, -S(O₂)-, or optionally substituted - N-,

m and n are each independently 0, 1, 2, 3 or 4; and pharmaceutically acceptable salts thereof.

10. (currently amended) A compound that is:

N-(4-methylbenzoyl)- N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(4-methylbenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(4-methylbenzoyl)-N'-(1-naphthyl)guanidine;

N-(4-methylbenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(4-tertbutylphenyl)guanidine;

N-(4-methylbenzoyl)-1-indolinylcarboximidamide;

N-(4-methylbenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(4-methylbenzoyl)-1-[7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline] carboximidamide;

N-(4-methylbenzoyl)-1-(1,2,3,4-tetrahydroquinoline)carboximidamide;

N-(4-methylbenzoyl)-N'-(2,5-dibromophenyl)guanidine;

N-(4-methylbenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(2,5-dichlorobenzoyl)- N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-(1-naphthyl)guanidine;

N-(2,5-chlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-(4-tertbutylphenyl)guanidine;

N-(2,5-dichlorobenzoyl)-1-indolinylcarboximidamide;

N-(2,5-dichlorobenzoyl)- N'-methyl-N'-(4-isopropylphenyl)guanidine;

N-(phenylacetyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(phenylacetyl)-N'-(4-isopropylphenyl)guanidine;

N-(phenylacetyl)-N'-(4-tert-butylphenyl)guanidine;

N-(phenylacetyl)-1-indolinylcarboximidamide;

N-(phenylacetyl)-1-(1,2,3,4-tetrahydroquinoline)carboximidamide;

N-(phenylacetyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(phenylacetyl)-N'-(4-isopropylphenyl)-N'-methylguanidine;

N-(adamantan-1-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(1-naphthyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(4-isopropylphenyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(4-tert-butylphenyl)guanidine;

N-(adamantan-1-carbonyl)-1-(indolinyl)carboximidamide;

N-(adamantan-1-carbonyl)-1-(1,2,3,4-tetrahydroquinolinyl)carboximidamide;

N-(adamantan-1-carbonyl)-N'-(2,5-dibromophenyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(4-isopropylphenyl)-N'-methyl)guanidine;

N-(4-chlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(4-chlorobenzoyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(4-chlorobenzoyl)-N'-(1-naphthyl)guanidine;

N-(4-chlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(4-chlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(4-chlorobenzoyl)-N'-(4-tert-butylphenyl)guanidine;

N-(4-chlorobenzoyl)-1-(indolinyl)carboximidamide;

N-(4-chlorobenzoyl)-1-(1,2,3,4-tetrahydroquinolinyl)carboximidamide;

N-(4-chlorobenzoyl)-N'-(2,5-dibromophenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(1-naphthyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(4-tert-butylphenyl)guanidine;

N-(3,4-dichlorobenzoyl)-1-(indolinyl)carboximidamide;

N-(3,4-dichlorobenzoyl)-1-(1,2,3,4-tetrahydroquinolinyl)carboximidamide;

N-(3,4-dichlorobenzoyl)-N'-methyl-N'-(4-isopropylphenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(1-naphthyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(4-isopropylphenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(4-tert-butylphenyl)guanidine;

N-(thiophen-2-carbonyl)-1-(indolinyl)carboximidamide;

N-(thiophen-2-carbonyl)-1-(1,2,3,4-tetrahydroquinolinyl)carboximidamide;

N-(thiophen-2-carbonyl)-N'-methyl-N'-(4-isopropylphenyl)guanidine;

N-(furan-2-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(furan-2-carbonyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(furan-2-carbonyl)-N'-(1-naphthyl)guanidine;

N-(furan-2-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(furan-2-carbonyl)-N'-(4-isopropylphenyl)guanidine;

N-(furan-2-carbonyl)-N'-(4-tert-butylphenyl)guanidine;

N-(furan-2-carbonyl)-1-(indolinyl)carboximidamide;

N-(furan-2-carbonyl)-1-(1,2,3,4-tetrahydroquinolinyl)carboximidamide;

N-(furan-2-carbonyl)-N'-(4-isopropylphenyl)-N'-methylguanidine;

N-(pyrdin-3-carbonyl)-N'-(1-naphthyl)guanidine;

N-(pyridin-3-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(pyridin-3-carbonyl)-N'-(4-isopropylphenyl)guanidine;

N-(pyridin-3-carbonyl)-N'-(4-tert-butylphenyl)guanidine;

N-(pyridin-3-carbonyl)-1-(indolinyl)carboximidamide;

N-(pyridin-3-carbonyl)-1-(1,2,3,4-tetrahydroquinolinyl)carboximidamide;

N-(4-methoxybenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;

N-(1-naphthoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(1-naphthoyl)-N'-(4-isopropylphenyl)guanidine;

N-(1-naphthoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-butoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(4-butoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-butoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(benzyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-methylbenzoyl)-N'-(3-dimethylaminopropyl)guanidine;

N-(4-methylbenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-methylbenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-methylbenzoyl)-N'-(1-naphthylmethyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;

N-(4-methylbenzoyl)-N'-(5-phenylpentyl)guanidine;

N-(4-methylbenzoyl)-N'-(3-phenoxypropyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-chlorobenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-chlorobenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-methoxybenzoyl)-N'-(3-dimethylaminopropyl)guanidine;

N-(4-methoxybenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-methoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-methoxybenzoyl)-N'-(2-(4-chlorophenylethyl)guanidine;

N-(4-methoxybenzoyl)-N'-(1-naphthylmethyl)guanidine;

N-(4-methoxybenzoyl)-N'-(3,4,5-trimethoxybenzyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(1-naphthylmethyl)guanidine;

N-(4-butoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-butoxybenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-butoxybenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;

N-(4-butoxybenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-butoxybenzoyl)-N'-(2-(3-indole)ethyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(2-(3-indole)ethyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(2-phenylethyl)guanidine;

N-(1-naphthoyl)-N'-(benzyl)guanidine;

N-(1-naphthoyl)-N'-(3-dimethylaminopropyl)guanidine;

N-(1-naphthoyl)-N'-(2-phenylethyl)guanidine;

N-(1-naphthoyl)-N'-(4-phenylbutyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(benzyl)guanidine;

N-(thiophen-2-carbony1)-N'-(3-dimethylaminopropyl)guanidine;

N-(thiophen-2-carbony1)-N'-(2-phenylethyl)guanidine;

N-(thiophen-2-carbony1)-N'-(4-phenylbutyl)guanidine;

N-(4-methylbenzoyl)-N'-(cyclohexyl)-N''-methylguanidine;

N-(4-methylbenzoyl)-N'-(4-phenylbutyl)-N''-methylguanidine;

N-(4-methoxybenzoyl)-N'-(5-phenylpentyl)guanidine;

N-(2-methylbenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(2-methylbenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(2-methylbenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(2-methylbenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-methoxybenzoyl)-N'-(2-phenoxypropyl)guanidine;

N-(4-butoxybenzoyl)-N'-(5-phenylpentyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-phenoxyethyl)guanidine;

N-(4-methoxybenzoyl)-N'-(2-phenoxyethyl)guanidine;

 $N\hbox{-}(4\hbox{-}ethoxybenzoyl)\hbox{-}N'\hbox{-}[(2\hbox{-}benzylthio)ethyl] guanidine;$

N-(4-ethoxybenzoyl)-N'- (3,4,5-trimethoxyphenyl)guanidine;

or a pharmaceutically acceptable salt of any of said compounds.

$$(R^2)_m$$
 $(R^3)_n$
 $(R^3)_n$

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

each R² and each R³ are each independently hydrogen, halogen, hydroxyl, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

m is an integer of from 0-6; and n is an integer of from 0-4; and pharmaceutically acceptable salts thereof.

$$(R^2)_m \qquad (R^3)_n$$

$$R \qquad N \qquad N$$

$$N \qquad N$$

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfonyl; optionally substituted alkylsulfonyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

each R² and each R³ are each independently hydrogen, halogen, hydroxyl, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

m is 0, 1 or 2; and n is 0, 1, 2, 3, 4, 5 or 6; and pharmaceutically acceptable salts thereof.

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

each R², each R³ and each R⁴ are each independently hydrogen, halogen, hydroxyl, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

m is 0, 1 or 2; and n and r are each independently 0, 1, 2, 3 or 4; and pharmaceutically acceptable salts thereof.

$$(R^{2})_{m}$$

$$(R^{2})_{m}$$

$$(R^{3})_{n}$$

$$(R^{3})_{n}$$

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylthio; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

each R² and each R³ are each independently hydrogen, halogen, hydroxyl, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

Y is optionally substituted methylene, -O-, -S-, -S(O)-, -S(O₂)-, or optionally substituted - N-,

m is an integer of from 0-6; and n is 0, 1, 2, 3 or 4; and pharmaceutically acceptable salts of those compounds.

$$(\mathbb{R}^{2})_{m}$$

$$(\mathbb{R}^{3})_{n}$$

$$(\mathbb{R}^{3})_{n}$$

wherein R is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl; optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

each R² and each R³ are independently hydrogen, halogen, hydroxyl, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

m is 0, 1 or 2; and n is an integer equal to 0-9; and pharmaceutically acceptable salts thereof.

$$(R^3)_n$$

$$(R^2)_m$$

$$(R^4)_r$$

wherein R is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl; optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

each R², each R³ and each R⁴ are each independently hydrogen, halogen, hydroxyl, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

m is 0, 1, 2, 3 or 4; and n and r are each independently 0, 1, 2, 3 or 4; and pharmaceutically acceptable salts thereof.

$$(R^3)_n$$

$$(R^2)_m$$

$$(R^4)_r$$

wherein R is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl; optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ is independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

each R², each R³ and each R⁴ are each independently hydrogen, halogen, hydroxyl, azido, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfinyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl;

m is an integer of from 0-6; and n and r are each independently 0, 1, 2, 3 or 4; and pharmaceutically acceptable salts thereof.

- 19. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein R is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl; optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms.
- 20. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein R is optionally substituted cyclic alkyl.
- 21. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein R is optionally substituted carbocyclic aryl.
- 22. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein R is optionally substituted phenyl or naphthyl.
- 23. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein R is optionally substituted heteroaromatic or heteroalicyclic.
- 24. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein R is optionally substituted carbocyclic aralkyl.
- 26. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein at least one R¹ group is hydrogen.
- 27. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein both R¹ groups are hydrogen.

- 28. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein at least one R¹ group is optionally substituted alkyl.
- 29. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein at least one R¹ group is alkyl having 1 to 3 carbon atoms.
- 30. (previously presented) A compound of any one of claims 7-9 or 12-18 wherein both R¹ groups are optionally substituted alkyl.
- 31. (previously presented) A method of treating a nerve degeneration disease comprising administering to a mammal suffering from or susceptible to said disease a therapeutically effective amount of a compound of any of claims 7-8 or 12-18.
- 32. (previously presented) A method of treating a neurodegenerative disease comprising administering to a mammal suffering from or susceptible to said disease a therapeutically effective amount of a compound of any of claims 7-8 or 12-18.
- 33. (previously presented) A method of treating Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome or Korsakoff's disease, Cerebral Palsy, or epilepsy, comprising administering to a mammal suffering from or susceptible to said disease a therapeutically effective amount of a compound of any of claims 7-8 or 12-18.
- 34. (previously presented) A method of treating or preventing nerve cell death or degeneration comprising administering to a mammal suffering from or susceptible to nerve cell death or degeneration a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18.

- 36. (previously presented) A method of treating a mammal suffering from or susceptible to stroke or heart attack comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18.
- 37. (previously presented) A method of treating a mammal suffering from or susceptible to brain or spinal cord trauma comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18.
- 38. (previously presented) A method of treating a mammal suffering from or susceptible to pain including chronic pain or neuropathic pain, peripheral necropathy, migraines, shingles, emesis, narcotic withdrawal symptoms or age-dependent dementia, comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18.
- 39. (previously presented) A method of treating a mammal suffering from or susceptible decreased blood flow or nutrient supply to retinal tissue or optic nerve, or retinal ischemia or trauma, or optic nerve injury, or glaucoma, comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18.
- 40. (previously presented) A method of treating a mammal suffering from or susceptible to post-surgical neurological deficits or neurological deficits associated with cardiac arrest, comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 7-8 or 12-18.
- 41. (previously presented) A method for treating an infection in a mammal, comprising administering to a mammal suffering from or susceptible to an infection an effective amount of an aminoglycoside antibiotic and a compound of any one of claims 7-8 or 12-18.

- 42. (original) The method of claim 41 wherein the mammal is suffering from an infection of Gram negative bacteria or Gram positive bacteria.
- 43. (previously presented) A method of claim 31 wherein the mammal is a human.
- 44. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of any one of claims 7-8 or 12-18 and a pharmaceutically acceptable carrier.
- 45. (previously presented) A compound of any one of claims 7-8 or 12-18 that is radiolabelled.
- 46. (previously presented) A method of treating a nerve degeneration disease comprising administering to a mammal suffering from or susceptible to the disease a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N-X-R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

47. (previously presented) A method of claim 46 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - R^3 \\
N & R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

48. (previously presented) A method of claim 46 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

49. (previously presented) A method of treating a neurodegenerative disease comprising administering to a mammal suffering from or susceptible to the disease a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
\downarrow R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylthio; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl;

optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

50. (previously presented) A method of claim 49 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N - R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

51. (previously presented) A method of claim 49 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

52. (previously presented) A method of treating Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome, Korsakoff's disease, Cerebral, or epilepsy, comprising administering to a mammal suffering from or susceptible to the disease a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfinyl;

optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

53. (previously presented) A method of claim 52 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N - R^3 \\
\downarrow R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

54. (previously presented) A method of claim 52 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
\downarrow R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

55. (previously presented) A method of treating nerve cell death or degeneration comprising administering to a mammal suffering from or susceptible to nerve cell death or degeneration a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N-X-R^3 \\
\downarrow R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

56. (previously presented) A method of claim 55 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - R^3 \\
\downarrow R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

57. (previously presented) A method of claim 55 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

- 58. (previously presented) The method of claim 55 wherein the nerve cell death or degeneration is associated with hypoxia, hypoglycemia, brain or spinal cord ischemia, retinal ischemia, or brain or spinal cord trauma.
- 59. (previously presented) A method of treating a mammal suffering from or susceptible to stroke or heart attach comprising administering to the mammal a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

60. (previously presented) A method of claim 59 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
\hline
N & N-R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

61. (previously presented) A method of claim 59 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

62. (previously presented) A method of treating a mammal suffering from or susceptible to brain or spinal cord trauma comprising administering to the mammal a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

63. (previously presented) A method of claim 62 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

64. (previously presented) A method of claim 62 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N - X - R^3 \\
R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

65. (previously presented) A method of treating a mammal suffering from or susceptible to pain including chronic pain or neuropathic pain, peripheral necropathy, migraines, shingles, emesis, narcotic withdraw symptoms or age-dependent dementia, comprising administering to the mammal a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c}
O \\
N \\
N \\
N \\
N \\
N \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylthio; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl;

optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

66. (previously presented) A method of claim 65 wherein the compound has the following Formula:

$$\begin{array}{c|c} O & N(R^1)_2 \\ \hline N & N-R^3 \\ R^2 \end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

67. (previously presented) A method of claim 65 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N-X-R^3 \\
R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

68. (previously presented) A method of treating a mammal suffering from or susceptible to decreased blood flow or nutrient supply to retinal tissue or optic nerve, or retinal ischemia or trauma, or optic nerve injury, or glaucoma, comprising administering to the mammal a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N - X - R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

69. (previously presented) A method of claim 68 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - R^3 \\
\downarrow R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

70. (previously presented) A method of claim 68 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - X - R^3 \\
R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

71. (previously presented) A method of treating a mammal suffering from or susceptible to post-surgical deficits or neurological deficits associated with cardiac arrest, comprising administering to the mammal a therapeutically effective amount of a compound of the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N - X - R^3 \\
\downarrow R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkoxy; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

72. (previously presented) A method of claim 71 wherein the compound has the following Formula:

$$\begin{array}{c|c}
O & N(R^1)_2 \\
N & N - R^3 \\
R^2
\end{array}$$

wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylthio; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted

heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

73. (previously presented) A method of claim 71 wherein the compound has the following Formula:

$$\begin{array}{c}
O & N(R^1)_2 \\
N - X - R^3 \\
\downarrow R^2
\end{array}$$

wherein X is an alkylene linkage; wherein R is an optionally substituted cyclic alkyl; an optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; optionally substituted aralkyl; optionally substituted heteroaralkyl; or optionally substituted heteroalicyclicalkyl;

each R¹ and R² are each independently hydrogen, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfinyl; optionally substituted alkylsulfonyl; optionally substituted or unsubstituted carbocyclic aryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and 1 to about 3 hetero atoms;

X is a chemical bond, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkynylene; and

R³ is an optionally substituted cyclic alkyl; optionally substituted carbocyclic aryl, optionally substituted alkylaryl; or optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; and pharmaceutically acceptable salts thereof.

- 74. (previously presented) A method of any one of claims 46 through 73 wherein R² is hydrogen.
- 75. (previously presented) A method of any one of claims 46 through 73 wherein R² is optionally substituted alkyl.
- 76. (previously presented) A method of any one of claims 46 through 73 wherein R^2 is C_{1-3} alkyl.
- 77. (previously presented) A method of any one of claims 46, 49, 52, 55, 59, 62, 65, 68 or 71 wherein the compound is:

N-(4-methylbenzoyl)- N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(4-methylbenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(4-methylbenzoyl)-N'-(1-naphthyl)guanidine;

N-(4-methylbenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(4-tertbutylphenyl)guanidine;

 $N\hbox{-}(4\hbox{-}methylbenzoyl)\hbox{-} 1\hbox{-}indolinylcarboximidamide;}$

N-(4-methylbenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(2,5-dibromophenyl)guanidine;

N-(4-methylbenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(2,5-dichlorobenzoyl)- N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-(1-naphthyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(2,5-dichlorobenzoyl)-N'-(4-tertbutylphenyl)guanidine;

N-(2,5-dichlorobenzoyl)- N'-methyl-N'-(4-isopropylphenyl)guanidine;

N-(phenylacetyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(phenylacetyl)-N'-(4-isopropylphenyl)guanidine;

N-(phenylacetyl)-N'-(4-tert-butylphenyl)guanidine;

N-(phenylacetyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(phenylacetyl)-N'-(4-isopropylphenyl)-N'-methylguanidine;

N-(adamantan-1-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine:

N-(adamantan-1-carbonyl)-N'-(1-naphthyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(4-isopropylphenyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(4-tert-butylphenyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(2,5-dibromophenyl)guanidine;

N-(adamantan-1-carbonyl)-N'-(4-isopropylphenyl)-N'-methyl)guanidine;

N-(4-chlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(4-chlorobenzoyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(4-chlorobenzoyl)-N'-(1-naphthyl)guanidine;

N-(4-chlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(4-chlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(4-chlorobenzoyl)-N'-(4-tert-butylphenyl)guanidine;

N-(4-chlorobenzoyl)-N'-(2,5-dibromophenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(1-naphthyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(4-tert-butylphenyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-methyl-N'-(4-isopropylphenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(1-naphthyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(4-isopropylphenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(4-tert-butylphenyl)guanidine;

N-(thiophen-2-carbonyl)-N'-methyl-N'-(4-isopropylphenyl)guanidine;

N-(furan-2-carbonyl)-N'-methyl-N'-(3-iodophenyl)guanidine;

N-(furan-2-carbonyl)-N'-methyl-N'-(3-methylthiophenyl)guanidine;

N-(furan-2-carbonyl)-N'-(1-naphthyl)guanidine;

N-(furan-2-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(furan-2-carbonyl)-N'-(4-isopropylphenyl)guanidine;

N-(furan-2-carbonyl)-N'-(4-tert-butylphenyl)guanidine;

N-(furan-2-carbonyl)-N'-(4-isopropylphenyl)-N'-methylguanidine;

N-(pyrdin-3-carbonyl)-N'-(1-naphthyl)guanidine;

N-(pyridin-3-carbonyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(pyridin-3-carbonyl)-N'-(4-isopropylphenyl)guanidine;

N-(pyridin-3-carbonyl)-N'-(4-tert-butylphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;

N-(1-naphthoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(1-naphthoyl)-N'-(4-isopropylphenyl)guanidine;

N-(1-naphthoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-butoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(4-butoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-butoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(4-isopropoxyphenyl)guanidine;

N-(4-methylbenzoyl)-N'-(benzyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-methylbenzoyl)-N'-(3-dimethylaminopropyl)guanidine;

N-(4-methylbenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-methylbenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-methylbenzoyl)-N'-(1-naphthylmethyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;

N-(4-methylbenzoyl)-N'-(5-phenylpentyl)guanidine;

N-(4-methylbenzoyl)-N'-(3-phenoxypropyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(benzyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-chlorobenzoyl)-N'-(benzyl)guanidine;

N-(4-chlorobenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-chlorobenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-methoxybenzoyl)-N'-(benzyl)guanidine;

N-(4-methoxybenzoyl)-N'-(3-dimethylaminopropyl)guanidine;

N (4 methoxybenzoyl) N' (2 phenethyl)guanidine;

N-(4-methoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-methoxybenzoyl)-N'-(2-(4-chlorophenylethyl)guanidine;

N-(4-methoxybenzoyl)-N'-(1-naphthylmethyl)guanidine;

N-(4-methoxybenzoyl)-N'-(3,4,5-trimethoxybenzyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(1-naphthylmethyl)guanidine;

N-(4-butoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-butoxybenzoyl)-N'-(2-phenethyl)guanidine;

N-(4-butoxybenzoyl)-N'-(2-(4-chlorophenyl)ethyl)guanidine;

N-(4-butoxybenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-butoxybenzoyl)-N'-(2-(3-indole)ethyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-(2-(3-indole)ethyl)guanidine;

N-(3,4,5-trimethoxybenzoyl)-N' (2-phenylethyl)guanidine;

N-(1-naphthoyl)-N'-(benzyl)guanidine;

N-(1-naphthoyl)-N'-(3-dimethylaminopropyl)guanidine;

N-(1-naphthoyl)-N'-(2-phenylethyl)guanidine;

N-(1-naphthoyl)-N'-(4-phenylbutyl)guanidine;

N-(thiophen-2-carbony1)-N'-(benzyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(3-dimethylaminopropyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(2-phenylethyl)guanidine;

N-(thiophen-2-carbony1)-N'-(4-phenylbutyl)guanidine;

 $N\hbox{-}(4\hbox{-methylbenzoyl})\hbox{-}N\hbox{''-methylguanidine;}$

N-(4-methylbenzoyl)-N'-(4-phenylbutyl)-N''-methylguanidine;

N-(4-methoxybenzoyl)-N'-(5-phenylpentyl)guanidine;

N-(2-methylbenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(2-methylbenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(2-methylbenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(2-methylbenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-methoxybenzoyl)-N'-(2-phenoxypropyl)guanidine;

N-(4-butoxybenzoyl)-N'-(5-phenylpentyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-phenoxyethyl)guanidine;

N-(4-methoxybenzoyl)-N'-(2-phenoxyethyl)guanidine;

N-(4-ethoxybenzoyl)-N'-[(2-benzylthio)ethyl]guanidine;

N-(4-ethoxybenzoyl)-N'- (3,4,5-trimethoxyphenyl)guanidine;

N-(2-methylbenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(2-methylbenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(3,4,5-trimethoxyphenyl)guanidine;

N-benzoyl-N'-(4-isopropylphenyl)guanidine;

N-benzoyl-N'-(4-isopropoxyphenyl)guanidine;

N-benzoyl-N'-(4-benzyloxyphenyl)guanidine;

N-benzoyl-N'-(2-isopropylphenyl)guanidine;

N-(2,6-dichlorophenacetyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(2,6-dichlorophenacetyl)-N'-(phenyl)guanidine;

N-(2,6-dichlorophenacetyl)-N'-(4-isopropyl)phenylguanidine;

N-(2,6-dichlorophenacetyl)-1-(indolinyl)carboxamidamide;

N-(2-chlorobenzoyl)-N'-(4-isopropyl)phenylguanidine;

N-(2-chlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(2-chlorobenzoyl)-1-(indolinyl)carboxamidamide;

N-(2,6-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(2,6-dichlorobenzoyl)-N'-(2-isopropylphenyl)guanidine;

N-(2,6-dichlorobenzoyl)-N'-(4-isopropylphenyl)guanidine;

N-(2,6-dichlorobenzoyl)-1-(indolinyl)carboxamidamide;

N-(2,6-dichlorobenzoyl)-N'-(trimethoxyphenyl)guanidine;

N-(2,3-dichlorobenzoyl)-N'-(4-isopropyl)phenylguanidine;

N-(2,3-dichlorobenzoyl)- 1-(indolinyl)carboxamidamide;

N-(2,3-dichlorobenzoyl)-N'-(4-benzyloxyphenyl)guanidine;

N-(4-methoxybenzoyl)-N'-(5-phenylpentyl)guanidine;

N-(2-methylbenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(2-methylbenzoyl)-N'-(3-phenylpropyl)guanidine;

N-(4-methoxybenzoyl)-N'-(3-phenoxypropyl)guanidine;

N-(4-butoxybenzoyl)-N'-(4-phenylbutyl)guanidine;

N-(4-methoxybenzoyl)-N'-(3-phenoxyethyl)guanidine;

N-(4-ethoxybenzoyl)-N'-(3-benzylthioethyl)guanidine;

N-benzoyl-N'-(4-phenylbutyl)guanidine;

N-benzoyl-N'-(3-phenoxypropyl)guanidine;

N-benzoyl-N'-(3,4,5-trimethoxybenzyl)guanidine;

N-benzoyl-N'-(2-benzylthioethyl)guanidine;

N-(4-methylbenzoyl)-N'-[(indol-3-yl)-2-ethyl]guanidine;

N-(4-chlorobenzoyl)-N'-[(indol-3-yl)-2-ethyl]guanidine;

N-(1-naphthoyl)-N'-[(indol-3-yl)-2-ethyl]guanidine;

N-(thiophen-2-carbonyl)-N'-[(indol-3-yl)-2-ethyl]guanidine;

N-(4-methylbenzoyl)-N'-butylguanidine;

N-(furan-2-carbonyl)-N'-(3-phenylpropyl)guanidine;

N-(4-methylbenzoyl)-N'-(2-benzylthioethyl)guanidine;

N-(4-methylbenzoyl)-N'-(1-indanyl)guanidine;

N-(N-(4-chlorobenzoyl)-N'-(1-indanyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(1-indanyl)guanidine;

N-(1-naphthoyl)-N'-[(imidazol-1-yl)-3-propyl]guanidine;

N-(furan-2-carbonyl)-N'-[(imidazol-1-yl)-3-propyl]guanidine;

N-(4-chlorobenzoyl)-N'-(2-benzylthioethyl)guanidine;

N-(3,4-dichlorobenzoyl)-N'-(2-benzylthioethyl)guanidine;

N-(1-naphthoyl)-N'-(2-benzylthioethyl)guanidine;

N-(thiophen-2-carbonyl)-N'-(2-benzylthioethyl)guanidine;

N-(4-methylbenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;

N-(3,4-dichlorobenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;

N-(3,4,5-trimethoxybenzoyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;

N-(furan-2-carbonyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;

N-(thiophen-2-carbonyl)-N'-[(thiophen-2-yl)-2-ethyl]guanidine;

N-(2,3-dichlorobenzoyl)-N'-(4-phenylbutyl]guanidine;

N-(2,5-dichlorobenzoyl)-N'-(4-phenylbutyl]guanidine;

N-(2,6-dichlorobenzoyl)-N'-(4-phenylbutyl]guanidine; or

N-(2,6-dichlorophenylacetyl)-N'-benzylguanidine; or a

pharmaceutically acceptable salt of any of said compounds.